Navigation Links
Transition Therapeutics Receives Remaining Upfront Payment from Elan Corporation, plc

TORONTO, Oct. 26 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") (NASDAQ: TTHI, TSX: TTH) announced the receipt of US$7.5 million representing the second half of the US$15 million upfront payment under the Company's global collaboration agreement with a subsidiary of Elan Corporation, plc ("Elan") (NYSE: ELN) for the Alzheimer's disease drug candidate ELND-005/AZD-103.

ELND-005/AZD-103 has completed Phase I clinical trials and the drug candidate appears to be safe and well tolerated at all doses and dosing regimes examined in approximately 110 subjects. The drug candidate was also shown to be orally bioavailable, cross the blood brain barrier, and achieve levels in the human brain and CSF that were shown to be effective in animal models for Alzheimer's disease.

Transition and its collaborator Elan remain on track to commence a Phase II clinical trial by the end of 2007 or early 2008.

About Transition

Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease and regenerative therapies E1-I.N.T.TM and GLP1-I.N.T.TM for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. Transition's shares are listed on the NASDAQ under the symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For additional information about the company, please visit

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release and may be superseded by more recent information we have disclosed in later press releases, filings with the OSC, SEC or otherwise. Except for historical information, this press release may contain forward-looking statements, relating to expectations, plans or prospects for Transition, including conducting clinical trials. These statements are based upon the current expectations and beliefs of Transition's management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include factors beyond Transition's control and the risk factors and other cautionary statements discussed in Transition's quarterly and annual filings with the Canadian commissions.

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
8. Infant receives first bloodless liver transplant
9. British MPs Say Prostate Cancer Receives Low Priority in the NHS
10. Fifth US Patient Receives Artificial Heart
11. Northfield Labs Receives FDA Comments
Post Your Comments:
(Date:11/27/2015)... PITTSBURGH, PA (PRWEB) , ... November 27, 2015 ... ... of how filthy the toilets were," said an inventor from Hillside, N.J. "Many ... this improved seat cover so that individuals will always be protected from germs." ...
(Date:11/27/2015)... ... November 27, 2015 , ... ProSidebar: Fashion is a set of ... With ProSidebar: Fasion, video editors can easily add an informative sidebar to any FCPX ... Utilize presets featuring self-animating drop zones, lines, bars, and text with the ease ...
(Date:11/27/2015)... ... 2015 , ... Intellitec Solutions announced today that they have ... as Microsoft’s official group for end users of Dynamics SL ERP software, the ... experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in ... for mental health and wellness consultation, has collaborated with a leading web-based marketplace ... knowledge gap experienced by parents and bring advice from parenting experts within their ...
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology: